

DAXOR CORP
Form DEF 14A
May 14, 2007

DAXOR CORPORATION
350 FIFTH AVENUE, SUITE 7120
NEW YORK, NY 10118

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD JUNE 15, 2007

NOTICE IS HEREBY GIVEN that the Annual Meeting of Shareholders of DAXOR CORPORATION (the Company) will be held at the principal office of the Company, 350 Fifth Avenue (Empire State Building), Suite 7120, New York City, on Friday, June 15, 2007 at 10:00 a.m., Eastern Standard Time, for the following purposes:

1. To elect a board of seven directors, each to serve for a term of one year and until his successor shall have been duly elected and qualified.
2. To transact such other business as may properly come before the meeting, or any adjournment thereof.

By Order of the Board of Directors,

Diane M. Meegan
Corporate Secretary

May 14, 2007

IF YOU DO NOT EXPECT TO BE PRESENT AT THE MEETING AND WISH YOUR SHARES TO BE VOTED, PLEASE SIGN, DATE AND MAIL THE ACCOMPANYING FORM OF PROXY AS PROMPTLY AS POSSIBLE IN THE ENCLOSED ENVELOPE.

TABLE OF CONTENTS

	<u>PAGE</u>
<u>ABOUT THE MEETING</u>	1, 2
<u>What is the purpose of the annual meeting?</u>	
<u>Who is entitled to vote?</u>	
<u>What constitutes a quorum?</u>	
<u>How do I vote?</u>	
<u>Can I change my vote after I submit my proxy card?</u>	
<u>What are the Board's recommendations?</u>	
<u>What is the Company's policy with respect to Board member attendance at the Annual meeting of shareholders?</u>	
<u>STOCK OWNERSHIP</u>	2,3
<u>How much Daxor stock do the Company directors and director nominees own?</u>	
<u>Section 16(a) Beneficial Ownership Reporting Compliance</u>	
<u>ITEM 1- NOMINATION OF BOARD</u>	3, 4, 5
Directors Standing for Election	
<u>ITEM 2- ELECTION OF THE BOARD OF DIRECTORS</u>	3
<u>NAMED EXECUTIVE OFFICERS</u>	
Company Officers	5, 6
<u>STOCK OPTIONS</u>	7
<u>THE AUDIT COMMITTEE</u>	
<u>Audit Committee Charter</u>	7
<u>Audit Committee Requirements</u>	7
<u>Audit Committee Responsibilities</u>	7
<u>Investment Risk Management</u>	7
<u>Processes</u>	7
<u>Additional Authority</u>	8
<u>Meetings</u>	8
<u>Reporting Requirements</u>	8
<u>Report of the Audit Committee</u>	8
<u>EXECUTIVE COMPENSATION</u>	
<u>Report of the Compensation Committee</u>	9
<u>Compensation Discussion and Analysis</u>	10
<u>Executive Compensation Table</u>	10
<u>Stock Option Grants</u>	11
<u>DIRECTORS COMPENSATION</u>	11
<u>FEES PAID TO INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS</u>	12
<u>STOCK OPTION PLAN</u>	12
<u>RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS</u>	13
<u>OTHER MATTERS & ADDITIONAL INFORMATION</u>	13

DAXOR CORPORATION
350 Fifth Avenue, Suite 7120
New York, NY 10118

PROXY STATEMENT

The accompanying proxy is solicited by and on behalf of the Board of Directors of Daxor Corporation, a New York Corporation (the Company), for use at the Annual Meeting of Shareholders to be held at the principal office of the Company, 350 Fifth Avenue, Suite 7120, New York City, on Friday, June 15, 2007 at 10:00 a.m., Eastern Standard Time (the Meeting), or any adjournment thereof. Shareholders of record at the close of business on May 14, 2007 will be entitled to vote at the meeting.

ABOUT THE MEETING

What is the purpose of the annual meeting?

At the Company's annual meeting, stockholders will act upon the matters outlined in the accompanying notice of meeting, including the election of directors and the stock option plan. In addition, the Company's management will report on the performance of the Company during 2006 and respond to questions from the stockholders.

Who is entitled to vote?

Only stockholders of record at the close of business on the record date, May 14, 2007 are entitled to receive notice of the annual meeting and to vote the shares of common stock that they held on that date at the meeting, or at any time and date to which the annual meeting may be properly adjourned or postponed. Each outstanding share entitles its holder to cast one vote on each matter to be voted upon.

What constitutes a quorum?

The presence at the meeting, in person or by proxy, of the holders of a majority of the shares of common stock outstanding on the record date will constitute a quorum, permitting the meeting to conduct its business. As of the record date May 14, 2007, shares of common stock of the Company were outstanding. Proxies received but marked as abstentions and broker non-votes will be included in the calculation of the number of shares considered to be present at the meeting.

How do I vote?

The Company will solicit proxies by mail. Arrangements will be made with brokerage houses and other custodians, nominees, and fiduciaries to forward solicitation material to the beneficial owners of the shares held of record by such persons, and the Company will reimburse them for the reasonable out-of-pocket expenses incurred by them in doing so.

Can I change my vote after I return my proxy card?

The shares represented by the accompanying proxy will be voted as directed with respect to the election of directors or, if no direction is indicated, will be voted in favor of election as directors of the nominees listed below. Each proxy executed and returned by a shareholder may be revoked at any time hereafter by giving written notice of such revocation to the Secretary of the Company, except as to any matter or matters upon which, prior to such revocation, a vote shall have been cast pursuant to the authority conferred by such proxy.

What are the Board's recommendations?

Unless you give other instructions on your proxy card, the persons named as proxy holders on the proxy card will vote in accordance with the recommendation of the Board of Directors. The Board's recommendation is set forth together with the description of each item in this proxy statement. In summary, the Board recommends a vote for election of the nominated slate of directors.

Edgar Filing: DAXOR CORP - Form DEF 14A

With respect to any other matter that properly comes before the meeting, the proxy holders will vote as recommended by the Board of Directors or, if no recommendation is given, at their own discretion.

The 10-K Financial Statement for the fiscal year ended December 31, 2006 is posted on the Company website at www.Daxor.com and is available by request from any shareholder.

The Board of Directors of the Company, on the recommendation of its audit committee consisting of a majority of independent directors, has selected the firm of Rotenberg Meril Solomon Bertiger & Guttilla, P.C. Certified Public Accountants, as the principal accountants for the current fiscal year. They have served in such capacity since 2005.

What is the Company's policy with respect to Board member attendance at annual meetings of stockholders?

Board members are encouraged to attend the Company's annual meetings of stockholders. Six of the Company's six board members attended the 2006 annual meeting of stockholders.

STOCK OWNERSHIP

How much stock does the Company's directors and director nominees own?

On March 31, 2007, the Company had issued and outstanding 4,603,418 shares of common stock, par value \$.01 per share (Common Stock), each of which entitled the holder to one vote. Voting is not cumulative.

The following table sets forth information as of May 14, 2007, with respect to all shareholders known by the Company to be beneficial owners of more than 5% of the outstanding Common shares, all Directors and all Director Nominees as a group. Except as noted below, each shareholder has sole voting and investment power with respect to shares owned.

Name of Beneficial Owner	Number of Common Shares Beneficially Owned	Percent
Joseph Feldschuh, M.D.	3,104,629	67.4%
Robert Willens	5,600	
Martin S. Wolpoff	2,000	
James A. Lombard	1,500	
Stephen Valentine, RA	500	
Philip Hudson	133,000	
All directors and nominees as a group	3,247,229	70.5 %

Directors, including the President, have options totaling 18,500 shares of Daxor stock exercisable at \$15.11 to \$25.32/share

Name	Number of Options Granted
Joseph Feldschuh, M.D	4,000
Philip Hudson	1,000
James A. Lombard	500
Robert Moussa	1,000
Stephen Valentine, RA	1,000
Robert Willens	10,000
Martin S. Wolpoff	1,000

(1) The percentage ownership calculation of each beneficial owner has been made on the basis of the number of shares outstanding of the Corporation's Common Stock as of the record date.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE Based upon a review of the filings with the Securities and Exchange Commission, the Company believes that all of the Company's directors and executive officers complied during 2006 with the reporting requirements of Section 16(a) of the Securities Act of 1934.

Item I. Nomination of Board of Directors

The Board of Directors has an Audit Committee and a Compensation and Stock Option Committee. The Board does not have a standing nominating committee or a charter with respect to the process for nominating directors for election to the Company's Board of Directors. The Company qualifies as a controlled company under American Stock Exchange (AMEX) rules, as Joseph Feldschuh, M.D. controls more than 50% of the Company's voting power, as evidenced by the Company's ownership records. As a result, The Amex continued listing standards do not require the Company to have a nominating committee or a written charter. Shareholders and members of the Company's Board submit nominees for election to the Company's Board of Directors to the entire Board for its consideration.

Item II. Election of Directors

Shareholders are being asked to elect an entire board of seven directors to serve on the Board of Directors of Daxor Corporation to hold office until the next annual meeting or until their successors shall have been duly elected and shall have qualified. The proxies will vote all proxies received FOR the election as directors of the nominees listed below if no direction to the contrary is given. In the event that any nominee is unable to serve, the proxy solicited herewith may be voted, in the discretion of the proxies, for the election of another person in his stead. The Board of Directors knows of no reason to anticipate that this will occur.

The following table sets forth the name, age, current and past five years business experience, directorship, and positions held with the Company by each person nominated for election as director.

Name and Age	Principal Occupation and Position with the Company	Director Continuously Since
Joseph Feldschuh, M.D., 71	Chairman of the Board of Directors and President of the Company (1)	1974
James Lombard, 72	Director of Administrative Services Division, New York City Council (Retired), Director (2)	1989
Martin S. Wolpoff, 64	Educational Consultant, Director, Administration Community School District (Retired), Director (3)	1989
Robert Willens, 60	Managing Director, Capital Markets, Lehman Brothers, Inc. Director (4)	2002
Stephen Valentine, RA, 53	President and Owner of Stephen Valentine Architect (5)	2004
Philip N. Hudson, 56	Minister, former registered principal w/NASD (6)	2005
Robert Moussa, 61	President and Owner of Robert Moussa & Assoc., Former President of Mallinckrodt Inc. International and CEO of Mallinckrodt Medical Inc. (7)	2006

-
- (1) **Joseph Feldschuh, M.D.** has been President of Daxor since 1974. He is on the staff of Montefiore Medical Center. From 1966 to 1983, Dr. Feldschuh was Director of the Cardiac Metabolic Laboratory at Metropolitan Hospital. He has been a Clinical Associate Professor in both medicine and pathology at New York Medical College and an Assistant Clinical Professor at Cornell Medical School. He performed the basic research at the College of Physicians and Surgeons (Columbia University) on the measurement and prediction of normal human blood volume. He is the co-inventor of the BVA-100 Blood Volume Analyzer and the inventor of the quantitative injection kit for the BVA-100. Originally trained in Endocrinology, he is Board Certified in Cardiology and Internal Medicine. Dr. Feldschuh is the Chief Scientist for the Company. He has been personally involved in measuring blood volume on more than 4,000 patients during his medical career. It is believed that Dr. Feldschuh has performed blood volume measurements on more patients than any other physician in the United States. In addition to his duties as Chief Scientist, Dr. Feldschuh is also responsible for managing the Company's investment portfolio.
- (2)* **James A. Lombard** holds an undergraduate degree in Business Administration (BBA) from Iona College and a Masters Degree (MBA) in Marketing, Banking, and Finance from New York University Graduate School of Business Administration. Mr. Lombard has retired as Director, Administrative Services Division of the City Council of New York and actively participates in civic and community affairs. Prior to joining the City Council, he worked in the banking industry and held various administrative positions with Citicorp and other major banks.
- (3)* **Martin S. Wolpoff** holds B.A., M.A. and M.S. degrees from the City University of New York. He has been active in community affairs since the 1970's. He has served on his local community board (as a member for over two decades and its chair for three years), community school board (member for nine years, president for three), Community Development Corporation (member for almost 10 years), and a member of the community advisory board for a New York City hospital. Mr. Wolpoff is retired from the New York City public school system, having served since 1965 as an educator, supervisor and administrator. He is currently an educational consultant, an adjunct university professor and the non-medical member of the Institutional Review Board at a local hospital.
- (4)* **Robert Willens** is a Managing Director in the Capital Markets department at Lehman Brothers, Inc., in New York. Mr. Willens specializes in tax and accounting issues and in this capacity advises most areas of the firm regarding the optimal structures for corporate capital transactions. In addition, he has been instrumental in developing certain financial products with a view towards insuring that these products will provide clients with the desired tax and accounting results. Prior to joining Lehman Brothers in 1987, Mr. Willens was a tax partner in the New York office of what was then known as Peat Marwick. Mr. Willens is a prolific author and has written Taxation of Corporate Capital Transactions, as well as over 200 articles for various professional journals. Each year of the past 10 years, Mr. Willens has been named to Institutional Investor's All-American Research Team. Mr. Willens has been selected, on four different occasions, as one of the 100 Most Influential Accountants in the United States by Accounting Today. Mr. Willens serves as Adjunct Professor (Finance Department) at Columbia University's Graduate School of Business where he teaches the course entitled Investment Banking Tax Factors.

- (5) **Stephen Valentine, RA** has contributed to the design of major commercial and institutional projects worldwide for more than two decades. At I.M. Pei and Partners, Mr. Valentine served as a senior architect and design team member for the highly-acclaimed United States Holocaust Memorial Museum in Washington D.C., and for New York's Jacob Javits Convention and Exhibition Center, the world's largest space-frame structure. Mr. Valentine was a senior design architect for the Hong Kong Convention and Exhibition Center, the landmark structure that was the host site in 1997 for the transfer of governmental authority from the United Kingdom to the People's Republic of China. His current project, Timeship, will be the world's first comprehensive facility devoted to life extension research that includes cryopreservation for both extinct and near extinct species, DNA, semen, eggs, embryos, and human organs for transplant. Mr. Valentine has taught at Pratt Institute as an adjunct professor in architecture for more than 12 years, where he previously received his Bachelor of Architecture in 1977. He is a recipient of the American Institute of Architects' School Medal.
- (7) **Philip N. Hudson** earned his undergraduate degree in Business Administration (BBA) from Trinity University (San Antonio, TX) in 1972. He started in the brokerage industry in 1973 as a securities and commodities broker. In 1980 he became a Registered Principal with the NASD and started his own brokerage firm. He has since left the industry. He is a partner in oil and gas ventures, which he oversees. For six years prior to joining the Board of Directors, he served as an unpaid advisor to the company. Mr. Hudson has been a shareholder of Daxor since 1996. Since 1985 he has volunteered his time in the pastoral ministry, with his wife, at Community Bible Church in San Antonio.
- (8) **Robert G. Moussa** successfully led a major healthcare company to over \$1 billion in sales. In 1997 he established his own consulting practice, Robert Moussa & Associates. From 1978 to 1997 he was at Mallinckrodt Inc. International and served as its President from 1995 to 1997. From 1992 to 1996 he served as President and Chief Executive Officer of Mallinckrodt Medical, Inc.

* (member of the Audit Committee)

NAMED EXECUTIVE OFFICERS

JOSEPH FELDSCHUH, MD, Dr. Feldschuh has been President and Chief Executive Officer of Daxor since 1974. He is on the staff of Montefiore Medical Center. From 1966 to 1983, Dr. Feldschuh was Director of the Cardiac Metabolic Laboratory at Metropolitan Hospital. He has been a Clinical Associate Professor in both medicine and pathology at New York Medical College and an Assistant Clinical Professor at Cornell Medical School. He performed the basic research at the College of Physicians and Surgeons (Columbia University) on the measurement and prediction of normal human blood volume. He is the co-inventor of the BVA-100 Blood Volume Analyzer and the inventor of the quantitative injection kit for the BVA-100. Originally trained in Endocrinology, he is Board Certified in Cardiology and Internal Medicine. Dr. Feldschuh is the Chief Scientist for the Company. He has been personally involved in measuring blood volume on more than 4,000 patients during his medical career. It is believed that Dr. Feldschuh has performed blood volume measurements on more patients than any other physician in the United States. In addition to his duties as Chief Scientist, Dr. Feldschuh is also responsible for managing the Company's investment portfolio.

STEPHEN FELDSCHUH, Promoted to Chief Operating Officer on January 1, 2007, earned his undergraduate degree in Business Administration (BS) from Boston University in 1988. He obtained his Master's degree (MBA) in Finance from Baruch College in 1997. After graduating college, he worked for Bear Sterns & Merrill Lynch as a Commodity Broker & Futures Trader. From 1992 to 1997, he

Edgar Filing: DAXOR CORP - Form DEF 14A

joined Daxor as Operations Manager with various responsibilities including Quality Assurance of the laboratory. From mid 1997 to 1999, Mr. Feldschuh was a financial analyst doing Mergers & Acquisitions in the staffing industry for Headway Corporate Resources. Mr. Feldschuh then worked for Delia's Inc. as a Financial Controller until 2001 when he rejoined Daxor Corporation as Vice President of Operations. In 2003, Mr. Feldschuh was named Chief Financial Officer. In January, 2007, he was named Chief Operating Officer and relinquished the title of Chief Financial Officer. Stephen Feldschuh is the son of Dr. Joseph Feldschuh, President and CEO.

DAVID FRANKEL, Promoted to Chief Financial Officer on January 1, 2007, joined Daxor Corporation at the end of 2005 as the Corporate Treasurer. Prior to joining Daxor, Mr. Frankel was employed as a Controller at Strategic Workforce Solutions in New York. Prior to that, Mr. Frankel was the Controller at Stern Stewart & Co. from 1997 to 2004, where he oversaw accounting for nine overseas offices and directly supervised a staff of six in the firm's New York Office.

JOHN REYES-GUERRA, Vice President of Sales and Marketing. Mr. Reyes-Guerra serves as a clinical coordinator for the various research studies supported by the Company and has 18 years of healthcare/medical product and service sales experience. Mr. Reyes-Guerra joined Daxor as the Northeast Regional Manager in 2002. In May 2004 he was promoted to Vice President of Sales and Marketing. He has been responsible for assembling the various sales teams as well as the support Personnel for the various clinical users. At this stage, ongoing clinical support is required for users of the blood volume analyzer. He has also coordinated the development of sales and marketing materials. Prior to Daxor, he held various sales and sales management positions with Toshiba Medical Systems, Stryker Medical, Picker Health Care Products, and BFI Medical Systems. Mr. Reyes-Guerra is a 1987 graduate of Elmira College.

EVERIS ENGSTROM, Vice President of Engineering has over 20 years of research and development and operations management experience in the medical device and consumer electronics industries. He has a broad range of expertise in systems engineering, operations management, financial analysis, electromechanical design, software engineering, failure analysis, and manufacturing processes. He is in charge of Daxor Oak Ridge Operations (DORO). Mr. Engstrom has been responsible for coordinating construction of the BVA-100 manufacturing facility. His responsibilities include coordination of other sub-contractors involved in the manufacturing of the BVA system. Prior to joining Daxor, Mr. Engstrom was the Project Manager/Group Manager of Hardware Engineering for Beckman Coulter. In this position, he led a 37 person Research and Development Group.

STOCK OPTIONS

As of December 31, 2006, there are 96,500 stock options outstanding with strike prices ranging from \$15.20 to \$25.32 per share. Of these outstanding options, 62,800 were vested as of December 31, 2006 and 33,700 were non-vested.

As of January 1, 2006, the Company adopted SFAS No. 123R which requires companies to recognize in their income statement the grant date fair value of stock options and other equity based compensation issued to employees.

At December 31, 2006 there is a total unvested stock based compensation of \$29,824 and a total weighted average remaining term of .66 years. Total share based compensation expense recorded in 2006 totaled \$77,980 which increased the net loss by \$.02 per share.

AUDIT COMMITTEE CHARTER

The Committee's function is one of oversight, recognizing that the Company's management is responsible for preparing the Company's financial statements, and the independent auditor is responsible for auditing those statements. In adopting this charter, the Board acknowledges that the Committee members are not employees for the Company and are not providing expert or special assurance as to the Company's financial statements to any professional certification as to the external auditor's work or auditing standards.

Each member of the Committee shall be entitled to rely on the integrity of those persons and organizations within and outside the Company that provides information to the Committee and the accuracy and completeness of the financial and other information provided to the Committee by such persons or organizations, absent actual knowledge to the contrary. The Company stock is listed on the American Stock Exchange and is governed by listing standards.

AUDIT COMMITTEE REQUIREMENTS

Each member qualifies as independent as defined in the Corporate Governance Guidelines. The Board includes at least one member who is an Audit Committee Financial Expert as such term may be defined from time to time by the SEC.

AUDIT COMMITTEE RESPONSIBILITIES

The Audit Committee's responsibilities must comply with Rule 10A-3(b) (2), (3), (4) and (5) under the Securities Exchange Act of 1934. The Audit Committee will discuss with management the Company's earnings press releases prior to their release, including the use of pro-forma or adjusted

non GAAP information, as well as financial information and earnings guidance provided to analysts and ratings agencies. It has been, and is the current policy of the company to use information only in accordance with GAAP standards.

INVESTMENT RISK MANAGEMENT

Members of the Board of Directors have the power to approve the Company's investments. Such policies are formally reviewed by the Board of Directors at least once a year. The Audit Committee reviews results quarterly. All individual investment decisions are made solely by Dr. Feldschuh. Dr. Feldschuh devotes approximately 10-15 % of his time, about 5-7.5 hours per week, on the portfolio. Additional information concerning investment policies can be found in the 2006 10-K, and investment results can be found in the 2006 10-K under Consolidated Statements of Income.

PROCESSES

Management shall prepare annually, for review and approval by the Audit Committee, detailed procedures and processes for carrying on the Audit Committee's duties and responsibilities.

ADDITIONAL AUTHORITY

The Audit Committee shall have the authority to direct an investigation by the independent auditors into any matter related to the Company's business and affairs. In addition, the Audit Committee shall have the authority to utilize internal company resources, and to retain such outside counsel and/or other resources as it deems necessary at any time in carrying out the duties of the Audit Committee.

MEETINGS

The Audit Committee will meet on an as needed basis, but not less frequently than quarterly. Meetings will be called as needed to discuss any significant issues, including those related to the review of any Form 10-Q by the Company's independent auditors.

It is intended that any management representative present at any meeting of the Audit Committee withdraw for a period at the end of each meeting so as to permit discussion in private with the independent auditors.

REPORTING REQUIREMENTS

Annually the Audit Committee will report to the Board of Directors that:

The Company's audited financial statements have been reviewed and discussed with the independent auditors, including all required SAS No. 61 communications.

The Audit Committee has executed its responsibility to oversee the independent auditors. In particular, the Audit Committee shall (a) require (and shall so report to the Board) that the independent auditors deliver to the Audit Committee a formal written statement delineating all relationships between such accountants and the Company and (b) engage in a dialogue with such auditors concerning whether the provision of permitted non-audit services is compatible with maintaining the auditor's independence, taking into account the opinions of management and internal auditors.

The Company's financial statements are included in the Company's Annual Report or Form 10-K.

The required Audit Committee duties and responsibilities have been met for the most recently completed fiscal year.

REPORT OF THE AUDIT COMMITTEE

The Audit Committee of Daxor Corporation (the Committee) is composed of three directors who, in the judgment of the Board of Directors, meet the independence requirements of our charter and the American Stock Exchange rules. The Committee operates under a charter adopted by the

Board of Directors. The primary function of the Audit Committee is to assist the Board of Directors in its oversight of the Company's financial reporting processes. Management is responsible for the Company's financial statements and overall reporting process, including the system of internal controls. The independent auditors are responsible for conducting annual audits and quarterly reviews of the Company's financial statements and expressing an opinion as to the conformity of the annual financial statements with generally accepted accounting principles.

The Committee submits the following report pursuant to SEC rules:

The Committee has reviewed and discussed with management and with Rotenberg Meril Solomon Bertiger & Guttilla, P.C., the Company's independent registered public accounting firm, the audited financial statements of the Company for the year ended December 31, 2006 (the Financial Statements).

Rotenberg Meril Solomon Bertiger & Guttilla, P.C. has advised the management of the Company and the Committee that it has discussed with them all the matters required to be discussed by Statement of Auditing Standards No. 61, as modified, which include among other items, matters related to the conduct of the audit of the Financial Statements.

The Committee has received from Rotenberg Meril Solomon Bertiger & Guttilla, P.C. the written disclosures and the letter required by Independence Standards Board Standard No. 1 (which relates to the auditor's independence from the Company and its related entities) and has discussed Rotenberg Meril Solomon Bertiger & Guttilla's independence with them.

Based upon the aforementioned review, discussions and representations of Rotenberg Meril Solomon Bertiger & Guttilla, P.C. and the unqualified audit opinion presented by Rotenberg Meril Solomon Bertiger & Guttilla, P.C. on the Financial Statements, the Committee recommended to the Board of Directors that the Financial Statements be included in the Company's Annual Report on Form 10-K, and that Rotenberg Meril Solomon Bertiger & Guttilla, P.C. be selected as the independent registered public accounting firm for the Company for fiscal 2007.

May 14, 2007

Members of the Audit Committee:

Robert Willens, Chairman

James Lombard

Martin S. Wolpoff

REPORT OF THE COMPENSATION COMMITTEE ON EXECUTIVE COMPENSATION

Joseph Feldschuh M.D., the President and Chief Executive Officer of Daxor, owns 67.4% of the Company's outstanding stock. Dr. Feldschuh is responsible for determining the annual salary and other compensation for executive officers and all other employees of the company.

Before the end of each year, the Chief Operating Officer and Chief Financial Officer prepare a schedule of recommended incentive bonuses and salary increases for executive officers and all other employees for Dr. Feldschuh to review. The recommendations are based on factors such as the individual's contribution to the overall success of the company, potential for advancement, and compensation history.

After making any adjustments required by Dr. Feldschuh, bonuses are generally paid by the end of the year.

COMPENSATION DISCUSSION AND ANALYSIS

This section provides information regarding the compensation program for our Chief Executive Officer, Chief Financial Officer and other key executives.

The overall objectives of Daxor's executive compensation programs are to:

Align interests of management and shareholders.

Retain key personnel.

Base Salary and Other Compensation

The salary of our chief executive officer, chief financial officer and other key executives is competitive with other companies in the Research and Development Stage. The company awards stock options to key executives in an effort to aid in their retention.

EXECUTIVE COMPENSATION

The following table sets forth certain information concerning the compensation of our Chief Executive Officer and each of our other named executive officers for the years ended December 31, 2006, 2005 and 2004.

Name & Position	Year	Salary (\$)	Bonus (\$)	All Other Compensation(1)(2)	Total Compensation
Joseph Feldschuh, M.D., Chief Executive Officer and President	2006	\$ 229,615	\$ 25,000	\$ 11,300	\$ 264,915
	2005	\$ 219,231	\$ 25,000	\$ 10,000	\$ 254,231
	2004	\$ 201,050	\$ 20,000	\$ 10,000	\$ 231,050
Stephen Feldschuh, Vice President of Operations and Chief Financial Officer (Promoted to Chief Operating Officer as of January 1, 2007)	2006	\$ 150,000	\$ 20,000	\$ 22,923	\$ 192,923
	2005	\$ 140,000	\$ 15,000	\$ 27,538	\$ 182,538
	2004	\$ 130,000	\$ 15,000	\$ 22,146	\$ 167,146
David Frankel, Treasurer (3) Joined Daxor in November, 2005 (Promoted to Chief Financial Officer as of January 1, 2007)	2006	\$ 95,000	\$ 2,500	0	\$ 97,500
	2005	\$ 5,709	0	0	\$ 5,709
Everis Engstrom, Vice President of Engineering	2006	\$ 80,649	0	0	\$ 80,649
John Reyes-Guerra, Vice President of Sales and Marketing	2006	\$ 125,000	\$ 25,000	\$ 6,000	\$ 156,000
	2005	\$ 125,000	\$ 25,000	\$ 10,734	\$ 160,734
	2004	\$ 112,659	\$ 25,000	\$ 6,000	\$ 143,659

(1) Car allowance paid to named executive.

(2) Payment in lieu of vacation.

Edgar Filing: DAXOR CORP - Form DEF 14A

For the year ended December 31, 2006, there are three employees whose total compensation was higher than one of the five named executive officers. The compensation of these three employees totaled \$249,806. Two of these individuals are senior account managers and the third is a clinical support manager.

STOCK OPTION GRANTS IN 2006

The following Stock Option Grants were made to the named executive officers during 2006:

Stephen Feldschuh (A)	12,500
David Frankel	2,500
Everis Engstrom	2,500
John Reyes-Guerra	1,000

(A) Of the 12,500 options granted to Stephen Feldschuh in 2006, 10,000 were issued as a replacement for options granted in 2001 which expired in 2006.

Aggregate Option Exercises in Last Fiscal Year and Year-End Option Values

The following table sets forth certain information concerning the year-end value of stock options of our Chief Executive Officer and the other named executive officers for the year ended December 31, 2006. There were no option exercises by the named executive officers during the fiscal year ended December 31, 2006.

Name	Number of Securities Underlying Unexercised Options Exercisable	Number of Securities Underlying Unexercised Options Unexercisable	Option Exercise Price	Option Expiration Date	Number of Shares of Stock That Have Not Vested	Market Value of Shares of Stock That Have Not Vested
Joseph Feldschuh	4,000	0	\$21.67-\$25.07	May 2009-June 2010	0	0
Stephen Feldschuh	8,000	13,500	\$15.77- \$25.07	July 2007 January 2011	13,500	\$200,475
David Frankel	0	2,500	\$21.45	January 2011	2,500	\$ 37,125
Everis Engstrom	0	2,500	\$15.77	December 2009	2,500	\$ 37,125
John Reyes-Guerra	22,000	1,000	\$15.20- \$25.07	October 2007-January 2011	1,000	\$ 14,850

DIRECTORS COMPENSATION

Our Directors are paid \$1,000 for attending the annual meeting and \$500 for each board meeting. The Company also reimburses Directors for any travel expense incurred to attend meetings. An employee director receives no fees for Board participation.

Edgar Filing: DAXOR CORP - Form DEF 14A

The compensation paid to the Directors in 2006 is set forth in the following table:

Name	Fees Paid	Option Awards	Total	Options Held
Phillip Hudson	\$ 2,500	0	\$ 2,500	1,000
James Lombard	\$ 2,500	0	\$ 2,500	500
Robert Moussa (A)	\$ 2,000	\$ 1,042	\$ 3,042	1,000
Stephen Valentine	\$ 2,500	0	\$ 2,500	1,000
Robert Willens (B)	\$ 2,500	0	\$ 2,500	10,000
Martin Wolpoff	\$ 2,500	0	\$ 2,500	1,000

(A) The options were granted to Robert Moussa in 2006.

(B) 2,000 options were granted to Robert Willens in April of 2007 and the remainder were granted prior to January 1, 2006

The Board of Directors met four times during 2006, of which 4 out of the 5 directors were in attendance at all of the meetings.

FEES PAID TO INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS

Audit Fees. The aggregate fees for professional services rendered by Rotenberg Meril Solomon Bertiger & Guttilla, P.C. for the audit of our financial statements included in our annual report on Form 10-K for the year ended December 31, 2006 and for the review of our financial statements included in our quarterly reports on Form 10-Q for the quarters ended March 31, 2006, June 30, 2006 and September 30, 2006 were \$104,185 for 2006. Comparable fees for the 2005 audit and three quarterly reviews amounted to \$73,537.

Audit Related Fees. The aggregate fees billed for audit-related services rendered by Rotenberg Meril Solomon Bertiger & Guttilla, P.C. were approximately \$ 0 and \$68,237 in 2006 and 2005, respectively. The fees billed in 2005 are for professional services rendered in connection with the audit procedures relating to the restatements of financial statements and SEC comment letters.

Tax Fees. The aggregate fees paid to Rotenberg Meril Solomon Bertiger & Guttilla, P.C. for tax compliance, tax planning and related services amounted to approximately \$ 5,000 in 2006 and \$6,000 in 2005.

All Other Fees. There were no other fees paid to Rotenberg Meril Solomon Bertiger & Guttilla, P.C., or services rendered by, in 2006 and 2005.

STOCK OPTION PLAN

In 1994, the Company adopted a stock option plan under Section 422(b) of the Internal Revenue Code wherein options would be granted to key employees, officers, and directors where the exercise would at least equal the fair market value on the date of the grant. The 1994 Company Stock Option Plan expired in June 2004. Under the new stock option plan filed in 2004, in accordance to Section 422 (b) of the Internal Revenue Code, options are granted to key employees, officers, directors, and consultants where the exercise equals at least 110% of the fair market value on the date of the grant. Subject to adjustment as provided in the Plan, the stock to be offered shall consist of shares of the Company s authorized but not issued Common Stock, \$.01 par value, and the aggregate amount of stock to be delivered upon exercise of all options granted under the Plan shall not exceed 200,000 of such shares, or 5% of the Company s outstanding shares, whichever is the larger number.

ITEM 2: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS

The Audit Committee of the Board has selected Rotenberg Meril Solomon Bertiger & Guttilla, (RMSB&G) PC, Certified Public Accountants, to serve as the independent registered public accountants for the fiscal year ending December 31, 2007. RMSB&G is familiar with our operations and the Audit Committee is satisfied with the professional reputation of RMSB&G in the auditing field, its personnel, their qualifications and independence.

OTHER MATTERS

As of the date of this proxy statement, the Company knows of no business that will be presented for consideration at the annual meeting other than the items referred to above. If any other matter is properly brought before the meeting for action by the stockholders, proxies in the enclosed form returned to the Company or other custodians will be voted in accordance with the recommendation of the Board of Directors or, in the absence of such a recommendation, in accordance with the judgment of the proxy holder.

ADDITIONAL INFORMATION

Stockholder Proposals for the 2008 Annual Meeting

Stockholders interested in presenting a proposal for consideration at the Company's annual meeting of stockholders in 2007 may do so by following the procedures prescribed in Rule 14a-8 under the Securities Exchange Act of 1934 and the Company's by-laws. To be eligible for inclusion in the proxy statement, the stockholder proposals must be received by the Company's President no later than December 15, 2007.

Stockholders interested in presenting a proposal at the Company's annual meeting of stockholders outside the procedures prescribed in Rule 14a-8 (i.e. a proposal to be presented at the annual meeting of stockholders in 2006 but not included in the Company's proxy statement) must be received by the Company's President no later than January 30, 2008 to be considered timely. Under the SEC's proxy voting rules, the Company may exercise discretionary voting authority on stockholder proposals received after such date.

By Order of the Board of Directors,

Diane M. Meegan
Corporate Secretary

May 14, 2007
New York, NY

A COPY OF THE COMPANY'S ANNUAL REPORT OR FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2006 MAY BE OBTAINED BY SHAREHOLDERS SOLICITED HEREBY (WITHOUT CHARGE) UPON WRITTEN REQUEST TO Diane M. Meegan, INVESTOR RELATIONS, DAXOR CORPORATION, 350 FIFTH AVENUE, SUITE 7120, NEW YORK, NEW YORK, 10118. THE 10-K IS ALSO ACCESSIBLE THROUGH THE COMPANY WEBSITE WWW.DAXOR.COM.

PROXY

THIS PROXY WILL BE VOTED AS DIRECTED, OR IF NO DIRECTION IS INDICATED, WILL BE VOTED FOR THE PROPOSALS.

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS.

	FOR	WITHHOLD AUTHORITY	Please mark your votes like this
1. ELECTION OF CLASS 1 DIRECTORS.	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>

(To withhold authority to vote for any individual nominee, strike a line through that nominee's name in the list below.)

Joseph Feldschuh, M.D., Robert Willens, James A. Lombard, Martin S. Wolpoff
Stephen Valentine, RA, Philip N. Hudson, Robert Moussa

	FOR	AGAINST	ABSTAIN
2. RATIFICATION OF INDEPENDENT AUDITORS	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rotenberg Meril Solomon Bertiger & Guttilla, PC			

COMPANY ID:

PROXY NUMBER:

ACCOUNT NUMBER:

Signature _____ **Signature** _____ **Date** _____

NOTE: Please sign as name appears hereon. When shares are held by joint owners, both should sign. When signing as attorney, executor, administrator, trustee or guardian, please give title as such, of a Corporation, please sign in full corporate name by President or other authorized officer, please sign in partnership name by authorized person.

PROXY

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

DAXOR CORPORATION

The undersigned appoints Joseph Feldschuh, M.D. and Martin Wolpoff, and each of them, as proxies, each with the power to appoint his substitute, and authorizes each of them to represent and to vote, as designated on the reverse hereof, all of the shares of common stock of Daxor Corporation held of record by the undersigned at the close of business on May 14, 2007 at the 2007 Annual Meeting of Shareholders of Daxor Corporation to be held on June 15, 2007 or at any adjournment thereof.

(Continued, and to be marked, dated and signed, on the other side)

